7-Ethyl-4,12-dioxa-7,17-diazatetracyclo[9.7.0.03,9.013,17]octadeca-1,3(9),10-triene-8,18-dione | 537034-76-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并恶嗪类
• 英文名称: 7-Ethyl-4,12-dioxa-7,17-diazatetracyclo[9.7.0.03,9.013,17]octadeca-1,3(9),10-triene-8,18-dione
• CAS: 537034-76-7
• 化学式: C₁₆H₁₈N₂O₄
• 分子量: 302.33
• InChiKey: KQKAZOQVLRXQTJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  22
• 可旋转键数：
  1
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  59.1
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  2,5-二羟基对苯二甲酸乙酯 在 盐酸 、 4-二甲氨基吡啶 、 potassium carbonate 、 1-羟基苯并三唑 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 、 三乙胺 、 potassium hydroxide 作用下， 反应 169.12h， 生成 7-Ethyl-4,12-dioxa-7,17-diazatetracyclo[9.7.0.03,9.013,17]octadeca-1,3(9),10-triene-8,18-dione
  参考文献：
  名称：

  Benzoxazinones as potent positive allosteric AMPA receptor modulators: Part I

  摘要：

  AMPA receptors (AMPARs) are an increasingly important therapeutic target in the CNS. Aniracetam, the first identified potentiator of AMPARs, led to the rigid and more potent CX614. This lead molecule was optimized in order to increase affinity towards the AMPA receptor. The substitution of the dioxine with a benzoxazinone ring system increased the activity and allowed further investigation of the sidechain SAR. (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2011.05.026

文献信息

• US7799913B2
  申请人：——

  公开号：US7799913B2

  公开（公告）日：2010-09-21
• [EN] CARBONYLBENZOXAZINE COMPOUNDS FOR ENHANCING GLUTAMATERGIC SYNAPTIC RESPONSES<br/>[FR] COMPOSES CARBONYLBENZOXAZINIQUES AMELIORANT LES REPONSES SYNAPTIQUES GLUTAMATERGIQUES
  申请人：CORTEX PHARMA INC

  公开号：WO2003045315A2

  公开（公告）日：2003-06-05

  This invention relates to the prevention and treatment of cerebral insufficiency, including enhancement of receptor functioning in synapses in brain networks responsible for higher order behaviors. These brain networks are involved in cognitive abilities related to memory impairment, such as is observed in a variety of dementias, and in imbalances in neuronal activity between different brain regions, as is suggested in disorders such as Parkinson's disease, schizophrenia and affective disorders. In a particular aspect, the present invention relates to compounds useful for treatment of such conditions, and methods of using these compounds for such treatment.